Hard to Treat Diseases (HTDS)

[Qork]

NEEEWSSSSSSSSSSSS
Hard To Treat Diseases (HTDS) - Large scale integrating project HEALTH 2009




HTDS - IBISS GROUP COMPETED FOR THE EUROPEAN COLLABORATIVE PROJECT - LARGE SCALE INTEGRATING PROJECT HEALTH 2009

BELGRADE, March 17 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS) http://www.htdsmedical.com/ is pleased to announce that the IBISS Group members from Slavica Biochem and part of a large International group of scientists, clinicians, management experts, small enterprises and industry from: Austria, Germany, Israel, Netherlands, Sweden, UK competed for the European Collaborative Project (large integrating project HEALTH 2009). Topics for single-stage submission and evaluation with a deadline of December 3, 2008 were successfully met by the company. Selection will be made sometime in 2009.

More details about the European Collaborative Project can be viewed by visiting these web site links.

http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/c all-for-proposals_en.html

http://ecentres.net/content/events/fp7-health-2009-single-stage_- _deadline_03_december_2008

The Indicative announced budget is EUR 476 million and focused on: BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

Slavica Biochem submission is on the Brain and brain-related diseases; as it relates to treatment of Multiple Sclerosis by means of stem cell therapy.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at . Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at

DATASOURCE: Hard to Treat Diseases


CONTACT: For medical and scientific dialogue inquiry only, please

contact Andrea Zecevic Hbsc. Msci; via e-mail at .

Andrea Zecevic obtained her degrees at the University of Toronto Canada.

Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief

Liaison Director between the China and Serbia operating subsidiaries. For any

corporate matters, readers should contact the company directly at